Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

Despite the success of checkpoint blockade in some cancer patients, there is an unmet need to improve outcomes. Targeting alternative pathways, such as costimulatory molecules (e.g. OX40, GITR, and 4-1BB), can enhance T cell immunity in tumor-bearing hosts. Here we describe the results from a phase...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Nat Commun
Egile Nagusiak: Duhen, Rebekka, Ballesteros-Merino, Carmen, Frye, Alexandra K., Tran, Eric, Rajamanickam, Venkatesh, Chang, Shu-Ching, Koguchi, Yoshinobu, Bifulco, Carlo B., Bernard, Brady, Leidner, Rom S., Curti, Brendan D., Fox, Bernard A., Urba, Walter J., Bell, R. Bryan, Weinberg, Andrew D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7886909/
https://ncbi.nlm.nih.gov/pubmed/33594075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-21383-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak